NAOV (NanoVibronix, Inc.) Short-Term Debt to Capital

NanoVibronix, Inc. (NAOV) develops miniature ultrasonic patches for pain management and wound healing. The business is currently focusing on expanding its B2B segment and implementing Medicare reimbursement codes to improve customer retention, with the indicator standing at 0.03. The price action shown below complements the profile of this developer of non-invasive urinary tract therapy systems, which has earned recognition among surgeons and urologists.

Optimized distribution logistics for NanoVibronix, Inc. ultrasound devices require monitoring the ratio of current liabilities under one year to equity, which measures the share of short-term borrowings within the equity structure to assess liquidity. An increase in this indicator signals a dependence on interbank financing, which, in the event of excessive debt, raises the risk of price volatility, whereas moderate values confirm the financial stability of the business.